Jefferies (NYSE:JEF) analyst Stephanie Wissink maintained a Hold rating on USANA Health (NYSE:USNA) on Thursday, setting a price target of $90, which is approximately 3.83% below the present share price of $93.58.
Wissink expects USANA Health to post earnings per share (EPS) of $1.89 for the fourth quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Hold rating of shares in USANA Health, with an average price target of $90.
The analysts price targets range from a high of $90 to a low of $90.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $336.84 million and a net profit of $53.72 million. The company's market cap is $1.87 billion.
According to TipRanks.com, Jefferies analyst Stephanie Wissink is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 4.7% and a 50.29% success rate.
USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, and Sense-beautiful science. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group. The Optimizers Nutritionals category consists of targeted supplements that support cardiovascular health, skeletal and structural health, and digestive health. The Foods Nutritionals category includes low-glycemic meal replacement shakes, snack bars, and other related products that provide optimal macro-nutrition. The Sense-beautiful science includes premium, science-based, personal care products that support healthy skin and hair by providing topical nourishment, moisturization, and protection. The firm's brand include Procosa and MagneCal D. The company was founded by Myron W. Wentz in September 1992 and is headquartered in Salt Lake City, UT.